NeOnc Technologies announced its Q4 2025 financial results and key clinical milestones, including completion of Phase 1 for NEO212 with a recommended Phase 2 dose set at 610 mg showing early anti-tumor signs. The NEO100 Phase 2a trial for recurrent IDH1-mutant glioma is fully enrolled, with interim data expected in August 2026, showing promising remission and progression-free survival rates without significant toxicity. The company strengthened its financial position through a $10 million PIPE financing and expanded leadership and scientific advisory boards. Upcoming plans include a Type B FDA meeting for NEO212 and a preliminary data readout for NEO100, positioning NeOnc for value-creating milestones soon.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Thor Explorations produced 19,153 ounces of gold in Q2 2026 from its Segilola mine in Nigeria, maintaining its full-year production guidance of 75,000 to 85,000 ounces. The company generated $77.3 million in revenue by selling 17,050 ounces at an ave...
Angelini Pharma has finalized its $4.1 billion acquisition of Catalyst Pharmaceuticals, enhancing its footprint in the U.S. market and strengthening its global leadership in brain health and rare diseases. The deal includes significant investments fr...
Zcash (ZEC) has gained over 16% in the past week, rallying from lows near $368 to around $552 following an 11% jump in one session. This surge is driven by anticipation of the Ironwood shielded pool upgrade expected around July 28, which addresses a ...
Greenwich LifeSciences is developing GLSI-100, an immunotherapy targeting HER2-positive breast cancer, currently in Phase 3 trials. The drug showed a 70-80% reduction in cancer recurrence in Phase 2b, outperforming existing treatments with no serious...
